Chapter 6
Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Raman Sharma, Madhulata Agarwal, Mayank Gupta, Somyata Somendra, and Shailendra K. Saxena

Abstract Novel Coronavirus Disease (COVID-19) has become a rapidly growing pandemic involving several nations. It is of serious concern and extreme challenge not only to the health personnel but also to the countries for containment. The causative organism is SARS-CoV-2, RNA virus of subgenus Sarbecovirus, similar to the SARS virus, and seventh member of the human coronavirus family responsible for this zoonotic infection. It binds to the human angiotensin converting enzyme (hACE-2) receptor and causes constitutional and respiratory symptoms. The major mode of transmission is human to human and the median incubation period is 4 days. The most common symptom as studied from various cohorts of COVID-19 patients are fever (83–98%) followed by fatigue (70%) and dry cough (59%); gastrointestinal symptoms are relatively uncommon differentiating it from SARS and MERS. Most of the SAR-CoV-2 infection are mild (80%) with a usual recovery period of 2 weeks. COVID-19 commonly affects males in the middle age and elderly age group, with highest case fatality (8–15%) among those aged >80 years. The disease begins with fever, dry cough, fatigue and myalgia progressing to dyspnoea and ARDS over 6 and 8 days post exposure, respectively. Underlying co-morbidities increase mortality in COVID-19. Poor prognostic factors are elderly, co-morbidities, severe lymphopaenia, high CRP and D-dimer >1 μg/L. The overall mortality rate ranges from 1.5 to 3.6%. COVID-19 has to be differen-
tiated from other viral and bacterial pneumonias as they are more common among healthy adults. Despite constant and vigorous efforts by researchers and health agencies, we are far from containment, cure or prevention by vaccine; hence right information and stringent prevention and control measures are the only weapon in the armoury to combat the ongoing infection.

**Keywords** COVID-19 · Clinical features · Differential diagnosis

### 6.1 Introduction

The world is yet again facing a global pandemic of zoonotic origin after the 2002 SARS (severe acute respiratory syndrome) and 2012 MERS (Middle East respiratory syndrome) era. Renowned microbiologists Macfarlane Burnet and David White predicted in 1972 that “the most likely forecast about the future of infectious diseases is that it will be very dull.” They further admitted that there was always a risk of “some wholly unexpected emergence of a new and dangerous infectious disease” (Burnet and White 1972). True to their prediction, in December 2019, a cluster of cases of pneumonia of unknown cause, linked to the local seafood market in Wuhan, capital of Hubei province in China heralded the now global pandemic of SARS-CoV-2, previous called the novel coronavirus 2019 (2019-nCoV) (Wuhan Municipal Health Commission 2019). It was in February 2020 the Director-General of WHO, Dr. Tedros Ghebreyesus, christened it as coronavirus disease 2019 (COVID-19) (World Health Organization 2020a). It was isolated from the human airway epithelial cells, and after the viral genomic sequencing was identified as the seventh member of the *betacoronavirus* family infecting humans, subfamily *Orthocoronavirinae*, order *nidovirales* and subgenus *Sarbecovirus* similar to the SARS virus but different clade with profound similarity to bat coronaviruses (Tan et al. 2020). It is a non-segmented, positive sense, single-stranded RNA virus. After the initial identification of the local cluster of cases in Wuhan, the epidemic peaked in China between late January and early February (WHO 2020a). The virus simultaneously spread rapidly worldwide by community transmission in Italy, Iran, Japan and South Korea and superspreading events affecting many nations across the globe causing the WHO to declare a public health emergency of international concern (PHEIC) on January 30th 2020 and a global pandemic on 12th March 2020 (WHO 2020b). Understanding of the disease is ever evolving since its emergence. SARS-CoV-2 is a pathogen with a naughty mix of virulence and contagiousness combined with human–animal interaction, urban crowding, global trade and tourism has made it a potential threat to mankind worldwide. Rapid containment of this pandemic needs enhancement of our knowledge regarding its transmission, incubation period, reproducibility, pathogenicity and clinical signs and symptoms and the differential diagnosis.
6.2 General Symptoms of Novel Coronavirus Disease 2019 (COVID-19)

COVID-19 has been studied extensively since its first appearance in Wuhan.

6.2.1 Transmission

Majority of the early cases (55%) clustered in Wuhan were initially transmitted due to direct contact with local seafood wholesale market and from residents in its local vicinity, but very soon person-to-person transmission was identified as the major mode of transmission (World Health Organization 2020b). SARS-CoV-2 like SARS virus binds to the human angiotensin-converting enzyme 2 receptor (hACE-2) located on type II alveolar and intestinal cells (Zhou et al. 2020a). Thus, the major mode of transmission is via airborne large droplets with a risk limited to ~6 ft from the patient (del Rio and Malani 2020). Due to large droplets borne transmission, infection can be prevented from spreading by using surgical face masks and airborne precautions. The other mode of person-to-person transmission is contact transmission via fomites, as the large droplets settle on surface and contaminate it, thus mandate decontamination of fomites and good hand hygiene.

6.2.2 Reproduction Number and Secondary Attack Rates

Reproduction number—the number of new cases arising from an infected case—was identified initially at 2.35 and declined to 1.05 over the period from December 2019 to January 2020 after travel restrictions were implemented in Wuhan (Kucharski et al. 2020). Reproduction number >1 implies that the epidemic will increase. Secondary attack rate (SAR), defined as the probability that an infection occurs among susceptible people within a specific group (such as household or close contacts), was identified to be 1–5% in China and 0.45% in the United States (WHO 2020c). These are important in deciding the importance of social interaction in causation of epidemic spread and highlight the significance of contact tracing.

6.2.3 Pathophysiology Behind Symptoms and Signs

An infected person moves through stages of replication over initial few days followed by a stage of adaptive immunity over the next few days (Karakike and Giamarellos-Bourboulis 2019). In the replicative stage the virus replicates, leading to influenza like illness characterized by mild symptoms due to direct cytopathic
effect of the virus. In the stage of adaptive immunity viral levels decline as immune system takes over, but the inflammatory cytokine storm leads to tissue destruction and clinical deterioration—which explains the phenomenon where patients remain relatively well initially before deteriorating suddenly. This implicates early initiation of antiviral therapies for better outcomes and use of immunosuppressive therapies in the adaptive immune stage.

### 6.2.4 Incubation Period (IP)

Incubation period for COVID-19 is defined as the interval between the potential earliest date of contact of the transmission source (wildlife or person with suspected or confirmed case) and the potential earliest date of symptom onset (i.e. cough, fever, fatigue or myalgia) and is within 14 days following exposure. Median incubation period being 4 days (interquartile range, 2–7 days; means 50% cases are dispersed during this period) (Guan et al. 2020).

### 6.2.5 Demographic Features and General Symptoms of COVID-19

Spectrum of illness ranges from mild disease (no or mild pneumonia) in 81% with a usual recovery period of about 2 weeks, through severe disease (dyspnoea, hypoxia or >50% lung involvement on imaging within 24–48 h) in 14% with a recovery period of about 3–6 weeks to critical disease (ARDS, sepsis, septic shock or MODS) in 5%; this was observed in data of 44,500 confirmed cases of COVID-19 as per information from Chinese Centre for Disease Control and Prevention (Wu and McGoogan 2020). COVID-19 predominantly affects males (58.1%), in particular of Asian ethnicity; this might be due to increased expression of hACE-2 receptor in them and also due to higher rates of smoking which further leads to increased expression of hACE-2 receptor (Cai 2020). But these are just speculations and further studies worldwide involving other ethnicities are needed. The age group affected predominantly are the middle aged and elderly (Median: 47 years; Range: 30–79 years), with very few cases reported among children (0.9–2%). Elderly are more severely affected and have higher case fatality (8–15%) (Zu et al. 2020).

Most studies (summarized in Table 6.1) on hospitalized patients from Wuhan reveal that the common symptoms of COVID-19 are fever (83–98%), fatigue (70%), dry cough (59%), anorexia (40%), myalgia (35%), dyspnoea (31%) and sputum production (27%). Fever in COVID-19 in various cohorts has been described as very low grade (axillary temperature >37.5 °C), intermittent and of prolonged duration (up to ~14 days). In the cohort of 1099 patients, in a study by Guan et al. (2020) only 43.8% had fever on admission and 88.7% had it during hospitalization.
Gastrointestinal symptoms such as nausea and vomiting (5%) and diarrhoea (3.8%) were relatively uncommon. Most common symptoms in most cohorts of COVID-19 are fever and cough, and gastrointestinal symptoms are relatively uncommon which differentiates COVID-19 from SARS and MERS. Asymptomatic infection too was observed but the frequency is unknown as was seen in the Diamond Princess cruise ship where out of the 619 people (17%) who were positive for SARS-CoV-2 (Japanese National Institute of Infectious Diseases 2020), 50% were asymptomatic with few of them showing objective abnormalities on imaging. Physical examination is nonspecific and unremarkable with <2% having pharyngitis or tonsillar enlargement.

### Table 6.1  General symptoms at the time of presentation in various cohorts

|                          | Guan et al. N = 1099 | Shi et al. N = 21 | Xu et al. N = 62 | Zhou et al. N = 191 | Yang et al. N = 52 |
|--------------------------|----------------------|------------------|------------------|---------------------|-------------------|
| **Constitutional symptoms** |                      |                  |                  |                     |                   |
| Fever                    | 975 (88.7%)          | 18 (86%)         | 48 (77%)         | 180 (94%)           | 46 (88%)          |
| Myalgia                  | 164 (14.9%)          |                  |                  | 29 (15%)            | 6 (12%)           |
| Headache                 | 150 (13.6%)          | 2 (10%)          | 21 (34%)         | 3 (6%)              |                   |
| **Upper respiratory symptoms** |                      |                  |                  |                     |                   |
| Rhinorrhoea              | 53 (4.8%)            | 5 (24%)          |                  | 3 (6%)              |                   |
| Sore throat              | 153 (13.9%)          |                  |                  |                     |                   |
| **Lower respiratory symptoms** |                      |                  |                  |                     |                   |
| Dyspnoea                 | 205 (18.7%)          | 9 (43%)          | 2 (3%)           | 56 (29%)            | 33 (64%)          |
| Chest tightness          | 5 (24%)              |                  |                  |                     |                   |
| Cough                    | 745 (67.8%)          | 15 (71%)         | 50 (81%)         | 151 (79%)           | 40 (77%)          |
| Sputum                   | 370 (33.7%)          | 3 (14%)          | 35 (56%)         | 44 (23%)            |                   |
| Haemoptysis              | 10 (0.9%)            |                  | 2 (3%)           |                     |                   |
| **Gastrointestinal symptoms** |                      |                  |                  |                     |                   |
| Nausea/vomiting          | 55 (5%)              | 2 (10%)          |                  | 7 (4%)              | 2 (6%)            |
| Diarrhoea                | 42 (3.8%)            | 1 (5%)           | 3 (8%)           | 9 (5%)              |                   |

Gastrointestinal symptoms such as nausea and vomiting (5%) and diarrhoea (3.8%) were relatively uncommon. Most common symptoms in most cohorts of COVID-19 are fever and cough, and gastrointestinal symptoms are relatively uncommon which differentiates COVID-19 from SARS and MERS. Asymptomatic infection too was observed but the frequency is unknown as was seen in the Diamond Princess cruise ship where out of the 619 people (17%) who were positive for SARS-CoV-2 (Japanese National Institute of Infectious Diseases 2020), 50% were asymptomatic with few of them showing objective abnormalities on imaging. Physical examination is nonspecific and unremarkable with <2% having pharyngitis or tonsillar enlargement.

### 6.2.6 COVID-19 in Children and Pregnancy

Symptomatic infection in children appears to be uncommon and if it does occur it is mild; only rarely severe infection has been documented. In a recent review by Chinese Centre for Disease Control and Prevention, less than 1% of the cases were reported in children less than 10 years of age (Wu and McGoogan 2020). In a study of 1391 children assessed and tested at Wuhan children’s hospital from 28th January to 26th February, 2020, a total of 171 (12.3%) were confirmed to have SARS-CoV-2 infection, with 104 males and 67 females. The median age of the children was 6.7 years. Cough was the most common symptom (48.5%), followed by pharyngeal erythema (46.2%) and fever (41.5%). Most common radiological finding was bilateral ground-glass opacities observed in 32.7% children. Radiological features were seen in
12 children with pneumonia without any symptoms and 27 (15.8%) had no radiological findings. As of March 8, 2020, 29 are stable in ward and 149 have been discharged with only single mortality of a child with underlying intussusceptions (Lu et al. 2020). In a large cohort study from China, <2% infection by SARS-COV-2 occurs in young individuals <20 years (Wu and McGoogan 2020).

There is very little data regarding COVID-19 in pregnancy, and knowledge regarding its intra-uterine and perinatal transmission is scarce. However, in a study of 18 pregnant females including both confirmed and suspected cases of SARS-CoV-2 infection only two cases of neonatal transmission were reported. One was by contact infection from the mother (Chen et al. 2020a). Thus, as of now the diagnosis and management of pregnant individuals is same as non-pregnant females. It is unknown if transmission occurs via breast milk; hence, airborne droplet and contact precautions are mandatory in lactating mothers or they have to avoid breastfeeding. So far the outcome studies in pregnancy seem inadequate due to the prolonged period of gestation.

### 6.3 Clinical Course of COVID-19 (Day-Wise)

The symptoms of COVID-19 (Fig. 6.1) initially begin with symptoms of fatigue, low-grade intermittent fever of prolonged duration, myalgia, dry cough and shortness of breath, which then either improves with early identification and conservative management (Fig. 6.2) or worsens and progresses to dyspnoea and productive cough. The median time to onset of dyspnoea from various cohorts was found to

![Timeline of COVID-19 after onset of illness](image)

Fig. 6.1 Timeline of COVID-19 after onset of illness
be 6 days following exposure. The median time to admission, development of ARDS and need for mechanical ventilation and ICU care was 8, 8.2 and 10 days, respectively. In a study (summarized in Table 6.2) by Zhou et al. (2020b) the median time to discharge from onset of illness was 22 days (IQR: 18–25 days), whereas the median time to death was 18.5 days (15–22 days). The median duration of fever was 12 days (8–13 days) and cough persisted for 19 days (IQR: 12–23 days) in survivors. Complications such as bilateral pneumonia followed by ARDS, sepsis and septic shock, acute cardiac injury, acute kidney injury and secondary infection developed at a median of 12 days (8–15 days), 9 days (7–13 days), 15 days (10–17 days), 15 days (13–19 days) and 17 days (13–19 days). The median duration of viral shedding was 20 days (IQR 17–24 days) from illness onset in survivors (Fig. 6.3a) vs. non-survivors (Fig. 6.3b) who continued shedding virus till death. In patients who received anti-retroviral with a median time of 14 days to their

![Fig. 6.2 Clinical progression and management of COVID-19](image-url)

**Table 6.2** Summary of course of illness in days in various cohorts of COVID-19

| Variables                        | Zhou et al. N = 199 | Huang et al. N = 41 |
|----------------------------------|---------------------|---------------------|
| **Onset following exposure in days** |                     |                     |
| Dyspnoea                         | 13                  | 8                   |
| Admission                        | 7                   |                     |
| ARDS                             | 12                  | 9                   |
| Mechanical ventilation/ICU       | 14.5                | 10.5                |
initiation, the median duration of viral shedding was 22 days (18–24 days). The median duration of viral shedding was 19 days (17–22 days) and 24 days (22–30 days) in patients with severe disease and critical disease, respectively.

### 6.4 Clinical Complications and Case Definitions

#### 6.4.1 Clinical Complications and Outcomes

The most common complications that develop in COVID-19 are bilateral pneumonia which may progress to ARDS, sepsis and septic shock, acute kidney injury (AKI) and others such as acute cardiac injury (arrhythmias, heart failure, MI), coagulopathy, rhabdomyolysis, hyponatremia and acidosis. Complications are more in severe disease vs. non-severe disease. In the study cohort of 1099 COVID-19 cases by Guan et al. (2020), bilateral pneumonia (91.1%) occurred
most commonly followed by ARDS (3.4%), septic shock (1.1%), AKI (0.5%) and coagulopathy (0.1%). In this cohort 926 (84%) had non-severe and 173 (16%) had severe disease. Underlying co-morbidities were more common among patients with severe disease than among non-severe disease (38.7% vs. 21.0%). Outcomes were as follows: 55 (5%) were discharged, 15 (1.4%) died, 9 (0.8%) recovered and 1029 (93.6%) remain hospitalized as of March 6, 2020. Overall mortality associated with COVID as of March 1, 2020, as estimated by the WHO, is 3.6% in China and 1.5% outside China. The mortality of COVID-19 (Fig. 6.4) is much less than that of SARS (9.6%) and MERS (34%). Case fatality rate of COVID-19 ranges from 5.8% in Wuhan to 0.7% in China. It is higher in elderly >70 years (8–15%). Overall case fatality is 2.3% (WHO 2020c). In most of the people with COVID-19, almost >80% have mild illness (Wu and McGoogan 2020).

6.4.2 Underlying Co-morbidities Complicating COVID-19

The major underlying co-morbidities that complicate the course of COVID-19 by increasing the severity of illness, use of mechanical ventilation and length of ICU stay and thus increase the mortality include uncontrolled hypertension, diabetes, coronary heart disease, hepatitis B, cerebrovascular disease, chronic obstructive airway disease and others like cancer, chronic kidney disease and immunodeficiency. In a study by Guan et al. (2020), hypertension (15%) was predominantly followed by diabetes (7.4%), the probable explanation to this could be due to hACE-2 receptor polymorphism in Asian population (Table 6.3).
6.4.3 Case Definitions (WHO 2020d)

Surveillance definition: A person with acute respiratory infection (sudden onset of at least one of the following: fever, cough, sore throat, shortness of breath) requiring hospitalization or not

AND

In the 14 days prior to symptom onset, meets at least one of the following epidemiological criteria:

- Was in close contact with a confirmed or probable case of COVID-19
- History of travel to areas of China with ongoing community transmission of SARS-CoV-2
- Worked in or attended a health care facility where COVID-19 patients were being treated

Probable case: A suspected case in whom testing for SARS-CoV-2 is inconclusive (result of the test reported by BSL4 lab) or in whom testing was positive on a pan-coronavirus assay.

Confirmed case: A person with laboratory confirmation of virus causing COVID-19 infection by RT-PCR of oropharyngeal or nasopharyngeal swab, irrespective of clinical signs and symptoms.

Table. 6.3 Summarized co-morbidities, complications and mortality in various cohorts of COVID-19

| Variables                                | Guan et al. N = 1099 (%) | Zhou et al. N = 191 (%) | Huang et al. N = 41 (%) |
|------------------------------------------|--------------------------|-------------------------|-------------------------|
| Hypertension                             | 15                       | 30                      | 15                      |
| Diabetes                                 | 7.4                      | 19                      | 20                      |
| Coronary heart disease                   | 2.5                      | 8                       | 15                      |
| Chronic obstructive pulmonary disease    | 1.1                      | 3                       | 2                       |
| Cerebrovascular disease                  | 1.4                      |                          |                         |
| Hepatitis B                              | 2.1                      |                          |                         |
| Cancer                                   | 0.9                      | 1                       | 2                       |
| Pneumonia                                | 91.1                     |                          |                         |
| Septic shock                             | 1.1                      | 20                      | 7                       |
| ARDS                                     | 3.4                      | 31                      | 29                      |
| Acute kidney injury                      | 0.5                      | 15                      | 7                       |
| Acute cardiac injury                     |                          | 17                      | 12                      |
| Coagulopathy                             | 0.1                      | 19                      |                         |
| Rhabdomyolysis                           | 0.2                      |                          |                         |
| Invasive mechanical ventilation          | 2.3                      | 17                      | 5                       |
| ECMO                                     | 5                        | 2                       | 5                       |
| CRRT                                     | 9                        | 5                       | 7                       |
| Mortality                                | 1.4                      | 28.3                    | 15                      |
6.5 Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Clinical diagnosis is based on signs and symptoms as described in previous sections along with substantiation from routine laboratory investigations and imaging and further confirmed by RT-PCR of nasopharyngeal or oropharyngeal swabs.

6.5.1 Routine Pathology and Biochemistry Lab Findings and Imaging in COVID-19

Major lab findings (Table 6.4) as in all other respiratory viral illness include leukopenia and lymphopaenia, elevated transaminases and D-dimer (Centres for Disease Control and Prevention 2020). Severe lymphopaenia, elevated C-reactive protein (CRP), elevated D-dimer (>1 μg/L), IL-6, ALT, serum ferritin, lactate dehydrogenase, creatine kinase, high-sensitivity cardiac troponin I, creatinine, pro-thrombin time and procalcitonin are associated with higher mortality (Guan et al. 2020).

The most common radiological findings on X-ray and CT thorax observed are bilateral ground-glass opacities (GGOs) with or without consolidation. Lesions predominantly involve bilateral lower lobes with peripheral distribution (Shi et al. 2020).

Table 6.4 Laboratory findings in patients of COVID-19 in various cohorts

| Variables                  | Guan et al. N = 1099 (%) | Zhou et al. N = 191 (%) | Huang et al. N = 41 (%) |
|----------------------------|-------------------------|-------------------------|-------------------------|
| Lymphopaenia <0.8 × 10^9/L | 83.2                    | 40                      | 63                      |
| Thrombocytopenia <100 × 10^9/L | 36.2                  | 7                       | 5                       |
| Elevated ALT >40 U/L       | 21.3                    | 31                      | 37                      |
| Elevated D-dimer >1 μg/L   | 46.4                    | 42                      |                         |
| Elevated CRP               | 60.7                    |                         |                         |
| Elevated creatinine        | 1.6                     | 4                       | 10                      |
| Elevated LDH >245 U/L      | 41                      | 67                      | 73                      |
| Elevated IL-6 >7.4 pg/mL   |                         |                         |                         |
| Serum ferritin >300 μg/L   |                         |                         | 80                      |
| Elevated creatinine kinase >185 U/L | 13.7       | 13                      | 33                      |
| High-sensitivity troponin I >28 pg/mL | 17                | 12                      |
| Increased procalcitonin ≥0.5 ng/mL | 5.5           | 9                       | 8                       |
| Increased prothrombin time ≥16 s | 6                  |                         |                         |
6.5.2 Poor Prognostic Factors in COVID-19

Strong independent predictors of high mortality are elderly (age ≥70 years); underlying co-morbidities such as uncontrolled hypertension, diabetes and coronary artery disease, chronic obstructive pulmonary disease and malignancy; severe lymphopaenia (<0.8 × 10^9/L) and D-dimer (>1 μg/L) (Chen et al. 2020b). Other poor prognostic factors are elevated C-reactive protein, LDH, ALT, serum ferritin, IL-6 and high-sensitivity cardiac troponin.

6.6 Differential Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

COVID-19 needs to be differentiated from other respiratory illnesses (Fig. 6.5) as well as other viral pneumonias (Table 6.5) associated with adenovirus, influenza, human metapneumovirus, parainfluenza, respiratory syncytial virus (RSV), rhinovirus and bacterial pneumonias (Ishiguro et al. 2019).

![Flow chart depicting general symptoms of COVID-19 and its mimics](Fig. 6.5)
6.7 Conclusions and Future Perspectives: What We Do Not Know Today?

Novel coronavirus disease (COVID-19) presents as mild illness in majority of cases with <5% developing life-threatening critical illness. Thus, timely recognition of appropriate history of exposure and prompt recognition of symptoms will help identify cases early and help in better contact tracing and early isolation. This will help bring down superspreading events and prevent further spread of the disease, also it will aid in reducing mortality related to COVID-19.

Since its origin in Wuhan with a cluster of cases of pneumonia of unknown origin, a long path has been tread in research on SARS-CoV-2. Our knowledge regarding this novel human coronavirus grows with each passing day, due to untiring efforts of researchers, epidemiologists and various health agencies, yet we are far from the magic bullet. There are lots of questions that remain unanswered, like its...
zoonotic origin, the frequency of asymptomatic cases, duration of viral shedding in
cases, period of infectivity, pathogenicity, long-term sequelae of the disease, its
consequences in pregnant individuals, development of a vaccine, etc. In order to
contain the pandemic effectively, the epidemiological questions that need answers
are regarding: shape of the disease pyramid, percentage infected who develop the
disease and proportion of those who seek health care. Amidst all the uncertainty, the
pandemic of SARS-CoV-2 grows unabated, fuelled by misinformation causing
panic worldwide. This information has to be counteracted by authentic scientific
narration. History has lot of lessons to offer regarding mitigating large epidemics,
provided we be wise and combat the epidemic by strict vigilance and surveillance,
stringent prevention and control practices and intervention strategies. In the era of
globalization and mass media, dissemination of life saving research can alone aid in
curbing the monstrously growing global epidemic of COVID-19.

Executive Summary

- SARS-CoV-2 was isolated from the human airway epithelial cells and was
  identified as the seventh member of the *betacoronavirus* family infecting
  humans, subfamily *Orthocoronavirinae* and subgenus *Sarbecovirus* similar
to the SARS virus but different clade with profound similarity to bat
coronaviruses.

- Clinical features of COVID-19
  - Transmitted mainly by human to human transmission and by contact
    with infected fomites.
  - Has a median incubation period of 4 days (Interquartile range: 2–7 days).
  - It predominantly affects middle aged and elderly males with a high case
    fatality of 8–15% in age group >70 years, affects <2% individuals
    <20 years.
  - The common symptoms are fever (low grade) in (83–98%), fatigue
    (70%) and dry cough (59%); GI symptoms are uncommon.
  - Most of the cases are of mild infection (80%) with a usual recovery
    period of 2 weeks; only 15 and 5% of cases are of severe and critical
    nature respectively.

- Clinical course of COVID-19
  - The disease begins with fever and dry cough and progresses to dyspnoea
    and ARDS and need for mechanical ventilation over 6, 8.2, and 10 days
    post exposure, respectively.

- Complications, outcome and case definition:
  - Most common complications are bilateral pneumonia progressing to
    ARDS, sepsis and septic shock.

(continued)
– Major underlying co-morbidities that complicate the course of COVID-19 include hypertension, diabetes, coronary heart disease, chronic obstructive pulmonary disease and malignancy.
– Overall mortality rate associated with COVID-19 ranges from 1.5 to 3.6%. The mortality rate of COVID-19 is much less than that of SARS (9.6%) and MERS (34%). Case fatality of COVID-19 is 2.3%.
– Confirmed case is defined as a person with laboratory confirmation of virus causing COVID-19 infection, irrespective of clinical signs and symptoms.

• Clinical diagnosis of COVID-19 and prognostic factors

– Clinical diagnosis is based on signs and symptoms along with routine laboratory investigations and imaging and confirmed by RT-PCR of nasopharyngeal or oropharyngeal swabs.
– Major lab findings as in all other respiratory viral illness include leukopenia and lymphopaenia, elevated transaminases, CRP and D-dimer.
– Most common radiological findings on X-ray and CT thorax observed are bilateral ground-glass opacities (GGOs), patchy consolidation or extensive exudative infiltrates.
– Strong independent predictors of high mortality are elderly (age ≥80 years); underlying co-morbidities such as uncontrolled hypertension, diabetes and coronary artery disease, chronic obstructive pulmonary disease and malignancy; severe lymphopaenia (≤0.8 \times 10^9/L) and D-dimer (≥1 μg/L).

• Differential diagnosis includes other viral pneumonia like adenovirus, influenza, human metapneumovirus, parainfluenza, respiratory syncytial virus (RSV), rhinovirus and bacterial pneumonia.

References

Burnet M, White DO (1972) Natural history of infectious disease, 4th edn. Cambridge University Press, Cambridge
Cai G (2020) Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCoV. MedRxiv. Published online Feb 28. https://doi.org/10.1101/2020.02.05.20020107
Centres for Disease Control and Prevention (2020) Interim clinical guidance for management of patients with confirmed 2019 novel coronavirus (2019-nCoV) infection, updated February 1 2, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed 14 Feb 2020
Chen H, Guo J, Wang C et al (2020a) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, Lancet 395:809–815
Chen N, Zhou M, Dong X et al (2020b) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507
del Rio C, Malani PN (2020) COVID-19—new insights on a rapidly changing epidemic. JAMA. Published online February 28, 2020. https://doi.org/10.1001/jama.2020.3072
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med
Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S (2020) Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30144-4
Ishiguro T, Kobayashi Y, Uozumi R et al (2019) Viral pneumonia requiring differentiation from acute and progressive diffuse interstitial lung diseases. Intern Med 58(24):3509–3519
Japanese National Institute of Infectious Diseases (2020) Field briefing: diamond princess COVID-19 cases, 20 Feb Update. https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html. Accessed 1 Mar 2020
Karakike E, Giamarellos-Bourboulis EJ (2019) Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 10:55
Lu X, Zhang L, Du H et al (2020) SARS-CoV-2 infection in children. N Engl J Med
Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20:425–434
Tan WJ, Zhao X, Ma XJ et al (2020) A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019–2020. China CDC Weekly 2:61–62
WHO (2020a) Director-General’s opening remarks at the media briefing on COVID-19—24 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-20200224. Accessed 26 Feb 2020
WHO (2020b) Coronavirus disease 2019 (COVID-19) situation report—36. February 25, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200225-sitrep-36-covid-19.pdf?sfvrsn=2791b4e0_2. Accessed 26 Feb 2020
WHO (2020c) Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-2019). February 16–24, 2020. http://www.who.int/docs/default-source/Coronavirus-who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 4 Mar 2020
WHO (2020d) Coronavirus disease (COVID-19) technical guidance: surveillance and case definitions. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions. Accessed 28 Feb 2020
World Health Organization (2020a) Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed 12 Feb 2020
World Health Organization (2020b) Novel coronavirus situation report—2. January 22, 2020. https://www.who.int/docs/default-source/Coronavirus-sitrep-2-2019-ncov.pdf. Accessed 23 Jan 2020
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Centre for Disease Control and Prevention. JAMA
Wuhan Municipal Health Commission (2019) Report of clustering pneumonia of unknown aetiology in Wuhan City. Wuhan Municipal Health Commission. http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
Zhou P, Yang X-L, Wang X-G et al (2020a) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in 2 humans and its potential bat origin. BioRxiv
Zhou F, Yu T, Du R et al (2020b) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062
Zu F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet